1189944-95-3
Chemical Structure
Metaxalone-d6
Synonym(s): AHR438-d6;NSC170959-d6
- No. CAS: 1189944-95-3
- Formula:C12H9D6NO3
- Molecular Weight:227.29
IUPAC Name: 5-((3,5-bis(methyl-d3)phenoxy)methyl)oxazolidin-2-one
InChIKey: IMWZZHHPURKASS-WFGJKAKNSA-N
SMILES: [2H]C([2H])([2H])C1=CC(C([2H])([2H])[2H])=CC(OCC2OC(NC2)=O)=C1
Biological Activity: Metaxalone-d6 is deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia[1][2][3].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Metaxalone-d6 | Metaxalone-d6 is deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metaxalone (Standard) | ≥98% | Metaxalone (Standard) is the analytical standard of Metaxalone. This product is intended for research and analytical applications. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metaxalone-d3 | 98.0% | Metaxalone-d3 is the deuterium labeled Metaxalone. Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metaxalone | 99.77% | Metaxalone (AHR438; NSC170959) is an FDA-approved muscle relaxant. Metaxalone acts mainly on the central nervous system and achieves muscle relaxation by inhibiting polysynaptic reflex arcs. In addition, Metaxalone is an inhibitor of MAO-A, which has anti-inflammatory and antioxidant effects. Metaxalone inhibits IL-1β-induced inflammatory phenotype, modulates NF-κB and other related signaling pathways, and decreases MAO-A expression and activity in IL-1β-treated microglia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.72
HY-126112RMephenoxalone (Standard) -
Similarity Score 0.64
HY-182485U-11634 -
Similarity Score 0.58
HY-W380450RViloxazine (Standard) -
Similarity Score 0.58
HY-W700716Metoprolol impurity 13 -
Similarity Score 0.58
HY-125784Viloxazine hydrochloride -
Similarity Score 0.58
HY-125784A(R)-Viloxazine hydrochloride -
Similarity Score 0.58
HY-125784B(S)-Viloxazine hydrochloride -
Similarity Score 0.57
HY-794162-((4-((2-Isopropoxyethoxy)methyl)phenoxy)methyl)oxirane -
Explore the MedChemAI to find more analogs
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Pallio G, et al. MAO-A Inhibition by Metaxalone Reverts IL-1β-Induced Inflammatory Phenotype in Microglial Cells. Int J Mol Sci. 2021;22(16):8425. [Content Brief]
- [3]. Stanko JR. Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner. Cranio. 1990 Jul;8(3):234-43. [Content Brief]
